Speciality European Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SPECIALITY EUROPEAN, and what generic and branded alternatives to SPECIALITY EUROPEAN drugs are available?
SPECIALITY EUROPEAN has one approved drug.
Drugs and US Patents for Speciality European
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Speciality European
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | 6,455,499 | ⤷ Subscribe |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | 5,843,901 | ⤷ Subscribe |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | 6,699,833 | ⤷ Subscribe |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | 6,423,686 | ⤷ Subscribe |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | 6,180,608 | ⤷ Subscribe |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | 5,968,895 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.